Amarin Stock Price, News & Analysis (NASDAQ:AMRN) $0.75 +0.01 (+1.35%) (As of 11/29/2023 ET) Add Compare Share Share Today's Range$0.73▼$0.7650-Day Range$0.66▼$0.9552-Week Range$0.65▼$2.23Volume919,825 shsAverage Volume1.26 million shsMarket Capitalization$302.87 millionP/E RatioN/ADividend YieldN/APrice Target$1.08 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Amarin MarketRank™ Stock AnalysisAnalyst RatingSell1.33 Rating ScoreUpside/Downside44.4% Upside$1.08 Price TargetShort InterestHealthy3.79% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.18) to ($0.19) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.79 out of 5 starsMedical Sector777th out of 949 stocksPharmaceutical Preparations Industry368th out of 432 stocks 2.7 Analyst's Opinion Consensus RatingAmarin has received a consensus rating of Sell. The company's average rating score is 1.33, and is based on no buy ratings, 1 hold rating, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.08, Amarin has a forecasted upside of 44.4% from its current price of $0.75.Amount of Analyst CoverageAmarin has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.79% of the outstanding shares of Amarin have been sold short.Short Interest Ratio / Days to CoverAmarin has a short interest ratio ("days to cover") of 9.8.Change versus previous monthShort interest in Amarin has recently decreased by 3.59%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAmarin does not currently pay a dividend.Dividend GrowthAmarin does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AMRN. Previous Next 3.8 News and Social Media Coverage News SentimentAmarin has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Amarin this week, compared to 2 articles on an average week.Search Interest9 people have searched for AMRN on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.MarketBeat Follows3 people have added Amarin to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amarin insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.81% of the stock of Amarin is held by insiders.Percentage Held by InstitutionsOnly 25.51% of the stock of Amarin is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Amarin are expected to decrease in the coming year, from ($0.18) to ($0.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amarin is -5.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amarin is -5.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmarin has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Amarin Stock (NASDAQ:AMRN)Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Read More AMRN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMRN Stock News HeadlinesNovember 21, 2023 | americanbankingnews.comAmarin (NASDAQ:AMRN) Receives Underweight Rating from JPMorgan Chase & Co.November 2, 2023 | finance.yahoo.comAmarin Corporation plc (NASDAQ:AMRN) Q3 2023 Earnings Call TranscriptNovember 30, 2023 | Edge On The Street (Ad)Gold Could Be Heading for Record Highs - But How to Play It?According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold. November 2, 2023 | finance.yahoo.comAre Investors Undervaluing Amarin Corporation plc (NASDAQ:AMRN) By 27%?November 1, 2023 | finance.yahoo.comAmarin Corp PLC (AMRN) Reports Q3 2023 Earnings: Net Revenues Down 27% Year-Over-YearNovember 1, 2023 | finance.yahoo.comAmarin (AMRN) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesNovember 1, 2023 | finance.yahoo.comAmarin Plc (AMRN) Q3 2023 Earnings Call TranscriptNovember 1, 2023 | finance.yahoo.comAmarin Reports Third Quarter 2023 Financial ResultsNovember 30, 2023 | Edge On The Street (Ad)Gold Could Be Heading for Record Highs - But How to Play It?According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold. November 1, 2023 | sfgate.comAmarin: Q3 Earnings SnapshotNovember 1, 2023 | morningstar.comAmarin Corp PLC ADR AMRNOctober 31, 2023 | finance.yahoo.comAmarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance OfficerOctober 26, 2023 | msn.comJefferies downgrades Amarin to 'hold'; shares downOctober 26, 2023 | finance.yahoo.comLatest Research Evaluating VASCEPA®/VAZKEPA® (icosapent ethyl) and Subgroups from the REDUCE-IT Landmark Outcomes Trial to be Presented at the American Heart Association (AHA) Scientific Sessions 2023October 19, 2023 | finance.yahoo.comAmarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023September 20, 2023 | finance.yahoo.comAmarin (NASDAQ:AMRN) Is In A Good Position To Deliver On Growth PlansSeptember 12, 2023 | finance.yahoo.comAmarin to Present at the 2023 Cantor Global Healthcare ConferenceAugust 31, 2023 | msn.comAmarin Corp - ADR (AMRN) Price Target Increased by 35.17% to 2.50August 8, 2023 | finance.yahoo.comAmarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in IsraelAugust 7, 2023 | benzinga.comScottish Medicines Consortium Accepts VAZKEPA® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1)August 7, 2023 | finanznachrichten.deAmarin Corporation plc: Scottish Medicines Consortium Accepts VAZKEPA (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in ScotlandAugust 3, 2023 | finance.yahoo.comAmarin (AMRN) Q2 Earnings and Revenues Surpass EstimatesAugust 3, 2023 | finance.yahoo.comAmarin Reports Second Quarter 2023 Financial ResultsAugust 2, 2023 | finanznachrichten.deAmarin Corporation plc: Amarin Reports Second Quarter 2023 Financial ResultsJuly 31, 2023 | finance.yahoo.comAmarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South KoreaJuly 27, 2023 | finance.yahoo.comLatest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) CongressJuly 25, 2023 | finance.yahoo.comAmarin Receives Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA® (icosapent ethyl) in SpainSee More Headlines Receive AMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amarin and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2023Today11/30/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/06/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AMRN CUSIPN/A CIK897448 Webwww.amarincorp.com Phone(531) 669-9020FaxN/AEmployees365Year Founded1991Price Target and Rating Average Stock Price Target$1.08 High Stock Price Target$1.25 Low Stock Price Target$1.00 Potential Upside/Downside+44.4%Consensus RatingSell Rating Score (0-4)1.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-105,800,000.00 Net Margins-16.27% Pretax Margin-17.99% Return on Equity-9.12% Return on Assets-6.09% Debt Debt-to-Equity RatioN/A Current Ratio2.69 Quick Ratio1.74 Sales & Book Value Annual Sales$369.19 million Price / Sales0.82 Cash FlowN/A Price / Cash FlowN/A Book Value$1.37 per share Price / Book0.55Miscellaneous Outstanding Shares403,830,000Free Float368,252,000Market Cap$302.87 million OptionableOptionable Beta2.11 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Thomas Charles Reilly (Age 51)Chief Financial Officer Comp: $856.49kDr. Steven B. Ketchum Ph.D. (Age 58)President of Research & Development and Chief Scientific Officer Comp: $991.19kMr. Aaron D. Berg (Age 60)Executive VP & President of U.S. Comp: $913.7kMr. Patrick HoltPresident, CEO & DirectorMr. Jordan Zwick (Age 36)Senior VP of Corporate Business Development & Investor Relations Ms. Donna PasekSenior Vice President of Human ResourcesMr. Laurent AbuafPresident of Europe & Senior VPDr. Nabil AbadirChief Medical Officer of Global Medical AffairsDr. David Keenan Ph.D.Executive VP of Technical Operations & President of EuropeMore ExecutivesKey CompetitorsErascaNASDAQ:ERASUroGen PharmaNASDAQ:URGNAvid BioservicesNASDAQ:CDMOArbutus BiopharmaNASDAQ:ABUSKalVista PharmaceuticalsNASDAQ:KALVView All CompetitorsInsiders & InstitutionsKynam Capital Management LPBought 22,957 shares on 11/15/2023Ownership: 2.977%13D Management LLCSold 2,579,723 shares on 11/15/2023Ownership: 0.372%Axxcess Wealth Management LLCBought 54,955 shares on 11/15/2023Ownership: 0.316%GSA Capital Partners LLPSold 44,691 shares on 11/15/2023Ownership: 0.011%Stadium Capital Management LLCBought 1,312,525 shares on 11/14/2023Ownership: 0.468%View All Insider TransactionsView All Institutional Transactions AMRN Stock Analysis - Frequently Asked Questions Should I buy or sell Amarin stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last twelve months. There are currently 2 sell ratings and 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "sell" AMRN shares. View AMRN analyst ratings or view top-rated stocks. What is Amarin's stock price target for 2024? 3 analysts have issued 1-year price objectives for Amarin's shares. Their AMRN share price targets range from $1.00 to $1.25. On average, they predict the company's stock price to reach $1.08 in the next year. This suggests a possible upside of 44.4% from the stock's current price. View analysts price targets for AMRN or view top-rated stocks among Wall Street analysts. How have AMRN shares performed in 2023? Amarin's stock was trading at $1.21 at the beginning of 2023. Since then, AMRN shares have decreased by 38.0% and is now trading at $0.75. View the best growth stocks for 2023 here. When is Amarin's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024. View our AMRN earnings forecast. How were Amarin's earnings last quarter? Amarin Co. plc (NASDAQ:AMRN) issued its quarterly earnings data on Wednesday, November, 1st. The biopharmaceutical company reported ($0.05) EPS for the quarter, hitting analysts' consensus estimates of ($0.05). The biopharmaceutical company earned $66.06 million during the quarter, compared to analysts' expectations of $57.56 million. Amarin had a negative net margin of 16.27% and a negative trailing twelve-month return on equity of 9.12%. What is John Thero's approval rating as Amarin's CEO? 43 employees have rated Amarin Chief Executive Officer John Thero on Glassdoor.com. John Thero has an approval rating of 93% among the company's employees. This puts John Thero in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at Amarin to a friend. What other stocks do shareholders of Amarin own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), Alibaba Group (BABA), Tesla (TSLA), Bank of America (BAC), Netflix (NFLX) and Novavax (NVAX). Who are Amarin's major shareholders? Amarin's stock is owned by many different institutional and retail investors. Top institutional shareholders include Kynam Capital Management LP (2.98%), SCP Investment LP (0.74%), Stadium Capital Management LLC (0.47%), 13D Management LLC (0.37%), Axxcess Wealth Management LLC (0.32%) and UBS Group AG (0.19%). Insiders that own company stock include David M Stack, Joseph S Zakrzewski, Michael Wayne Kalb, Olsen Per Wold, Patrick Holt and Steven B Ketchum. View institutional ownership trends. How do I buy shares of Amarin? Shares of AMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. Does Amarin have any subsidiaries? The following companies are subsidiares of Amarin: Amarin France SAS, Amarin Germany GmbH, Amarin Italy S.r.l, Amarin Pharma Inc., Amarin Pharmaceuticals Ireland Limited, Amarin Switzerland GmbH, Amarin UK Limited, Ester Neurosciences, and Ester Neurosciences Limited.Read More This page (NASDAQ:AMRN) was last updated on 11/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarin Co. plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.